No Data
Are Investors Undervaluing InventisBio Co., Limited (SHSE:688382) By 38%?
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Yifang Bio (688382.SH): Shareholder ABA-Bio intends to reduce its Shareholding by no more than 1.60%.
On April 2, Gelonghui reported that Yi Fang Biotechnology (688382.SH) announced that the shareholder ABA-Bio has issued a notice regarding the shareholder Shareholding plan, proposing to reduce its holdings of the company's shares by a total of no more than 9.23 million shares through centralized bidding and block Trade, with a reduction ratio not exceeding 1.60% of the company's total equity. The Shareholding period is within three months after 15 trading days from the date of this announcement, and the Shareholding price will be determined according to market prices.
Yifang Biotechnology (688382.SH): Suzhou Likang and others have cumulatively reduced their shareholding by 2.79%.
On March 26, Gelonghui reported that Yifang Bio (688382.SH) announced that as of the date of this announcement, LAVApex, LAVAlpha, LAVInventis, and Suzhou Likang have cumulatively reduced their shareholding of the company by 16,148,818 shares through centralized bidding and block trading, accounting for 2.79% of the company's total share capital. Based on their own shareholding arrangements, the aforementioned shareholders have decided to terminate this shareholding reduction plan early.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Yifang Biotechnology (688382.SH): Results of the Phase II clinical study of D-2570 for treating psoriasis will be announced at the 2025 USA Dermatology Annual Meeting.
Yifang Biotechnology (688382.SH) announced that its independently developed TYK2 inhibitor D-2570 is used for the treatment of...
